GlobeNewswire

BlueData Partners with Computacenter to Provide Big-Data-as-a-Service in Germany

Dela

Europe's Leading Independent Provider of IT Infrastructure Services Will Deliver BlueData's Containerized Big Data Platform in the German Market

 

SANTA CLARA, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- BlueData®, provider of the leading Big-Data-as-a-Service (BDaaS) software platform today announced a partnership with Computacenter Germany. The agreement will enable the IT infrastructure services provider to offer BlueData EPIC software to their enterprise IT customers in the German market.

"Enabling users through the efficient and secure provision of data on-demand means connecting them to meaningful information held in core systems and data center infrastructures, both on or off customers' premises and in the cloud," said Dr. Peter Meitz, lead consultant and solution architect for Big Data at Computacenter Germany. "BlueData is a powerful and innovative solution for Big-Data-as-a-Service and hybrid IT, and it will add huge value to our customers in this area."

BlueData has earned recognition for its innovations in using Docker containers to streamline the provisioning of Big Data workloads in an on-demand, elastic, and multi-tenant architecture. Using BlueData's EPIC platform, IT organizations can improve agility and reduce costs for their Big Data infrastructure - with the ability to spin up instant clusters for Hadoop, Spark, and other large-scale distributed frameworks - while ensuring enterprise-class performance and security.

The company recently announced support for GPU acceleration and deep learning tools (e.g. BigDLTensorFlow), and introduced initial availability for BlueData EPIC on Google Cloud Platform and Microsoft Azure in addition to Amazon Web Services. BlueData is the first and only Big-Data-as-a-Service solution that can be implemented on-premises, in the public cloud, or in hybrid and multi-cloud deployment models.

"Enterprises in all geographies are embarking on digital transformation and they see the promise of Big Data analytics, data science, and machine learning technologies," said Kevin Dunn, BlueData's director of sales for Europe, Middle East, and Africa. "But they need a faster, simpler, easier, and more cost-effective deployment model. BlueData's solution delivers dramatically faster-time-to-value for these organizations."

BlueData is building strong partnerships to establish its worldwide presence, and the company accelerated its momentum and expansion into new international markets over this past year with 228% annual growth.

"Computacenter is widely regarded as the 'go to' IT provider for many businesses and government organizations throughout Europe," said Dunn. "We're excited to partner with Computacenter Germany to further extend our global reach as the leading Big-Data-as-Service software platform. Together, we can deliver an end-to-end solution to unlock the business value of Big Data for our joint customers."

BlueData is participating and speaking at events in Germany and the UK over the coming months, including DataWorks Summit Berlin (April 16-19) and Strata Data Conference London (May 22-24):

About BlueData Software, Inc.
BlueData is transforming how enterprises deploy their Big Data applications and infrastructure. The BlueData EPIC(TM) software platform uses Docker container technology to make it easier, faster, and more cost-effective for enterprises of all sizes to leverage Big Data - enabling Big-Data-as-a-Service either on-premises, in the cloud, or in a hybrid architecture. With BlueData, they can spin up virtual Hadoop or Spark clusters within minutes, providing data scientists with on-demand access to the applications, data, and infrastructure they need. Based in Santa Clara, California, BlueData was founded by VMware veterans and its investors including Amplify Partners, Atlantic Bridge, Dell Technologies Capital, Ignition Partners, and Intel Capital. To learn more about BlueData, visit www.bluedata.com or follow @bluedata.

Press Contact
Jordan Tewell
10Fold
415.800.5385
bluedata@10Fold.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BlueData via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum